GTCbio Announces its Inaugural Ocular Diseases & Drug Discovery conference
GTCbio Announces its Inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, Pennsylvania.
[ClickPress, Thu Feb 19 2009] Due to the unmet needs of ocular disease drug therapies and the growing population of aging individuals, GTCbio is proud to announce its inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, PA.
In 2005, the National Eye Institute (NEI) estimated that the annual cost of vision impairment and eye disease to the United States was $68 billion. Not only are eye diseases costly to the US, they also impact the quality of life of over 34 million people, causing lost productivity, reduced independence, diminished quality of life, increased depression and accelerated mortality. By 2020, this number is expected to grow to over 50 million.
To help promote the discovery and developments of ocular disease, GTCbio is bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research & drugs available in combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, uveitis and other eye diseases at the Ocular Diseases & Drug Discovery conference.
The keynote presentation will be given by Pete Adamson, Head of Research for Ophthiris at GlaxoSmithKline
For more information on attending, presenting a poster, or sponsoring, please visit http://gtcbio.com/conferenceDetails.aspx?id=143
GTCbio organizes scientific conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO 434 W. Foothill Blvd. Monrovia, CA 91016 Tel: (626) 256-6405 fax: (626) 256-6460 email: email@example.com